trending Market Intelligence /marketintelligence/en/news-insights/trending/jf-a0udu6jszahtfhdnvbg2 content esgSubNav
In This List

Akebia Therapeutics prices offering to raise $89M

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Akebia Therapeutics prices offering to raise $89M

Akebia Therapeutics, Inc. priced its previously announced stock offering, looking to raise $89 million via the sale of 8.5 million shares at $10.50 each.

Morgan Stanley is acting as sole book-running manager for the Cambridge, Mass.-based biotechnology company's offering, expected to close by March 27.

The offering's underwriter has an option to buy an additional 1,275,000 shares.

Akebia plans to use the net proceeds for the continued clinical development and optimization of the vadadustat program, meant to treat anemia associated with chronic kidney disease.